Clinical Trials

Who Is Doing What (Gene Therapy), And Where?

Published in Vaccine Weekly, April 3rd, 1995

According to a report by Frost & Sullivan, cancer gene therapy is expected to account for as much as 94% of the gene therapy revenues as early as 1997 and expected to reach projected revenues of $1.25 billion by the year 2000.

By the end of 1994, the Recombinant DNA Advisory Committee (RAC) had approved 42 trials related to gene insertion as a cancer therapeutic and cancer vaccines, reports Gail Dutton in the March 1, 1995, issue of Genetic Engineering News. Following is a partial list of companies conducting research and clinical trials in the area of cancer gene therapy and cancer vaccines:

Canji/Imagenetics Inc.

Canji, based in San...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry